Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Health policy instruments such as the public financing of health technologies (e.g., new drugs, vaccines) entail consequences in multiple domains. Fundamentally, public health policies aim at increasing the uptake of effective and efficient interventions and at subsequently leading to better health benefits (e.g., premature mortality and morbidity averted). In addition, public health policies can provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, public policies such as social and health insurance programs can prevent illness-related impoverishment and procure financial risk protection. Furthermore, public policies can improve the distribution of health in the population and promote the equalization of health among individuals. Extended cost-effectiveness analysis was developed to address health policy assessment, specifically to evaluate the health and financial consequences of public policies in four domains: (1) the health gains; (2) the financial risk protection benefits; (3) the total costs to the policy makers; and (4) the distributional benefits. Here, we present a tutorial that describes both the intent of extended cost-effectiveness analysis and its keys to allow easy implementation for health policy assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Estimated distribution across income quintiles in Ethiopia of: (a) rotavirus-related deaths averted; (b) rotavirus-related private expenditures crowded out; and (c) financial risk protection afforded (measured by a money-metric value of insurance), with universal public finance of rotavirus immunization. Source: based on estimates from [48]](https://figures.cochat.ai/paper-figures/1d447dbc62f840eead20b9e5b514fe5c/extended-cost-effectiveness-analysis-for-health-policy-assessment-a-tutorial-figure-3.jpg)
![Fig. 4 Deaths averted and financial risk protection (measured by a money-metric value of insurance) afforded with universal public finance for rotavirus immunization, per $1 million spent, India (vaccine price of $5.0) and Ethiopia (vaccine price of $0.40). Income quintiles: I = poorest, II = poorer, III = middle, IV = richer, V = richest. Source: based on estimates from [48]](https://figures.cochat.ai/paper-figures/5dc824a165a941adb521464e1fcb18c2/extended-cost-effectiveness-analysis-for-health-policy-assessment-a-tutorial-figure-4.jpg)
![Fig. 5 Financial risk protection afforded (poverty cases averted) vs. health gains (deaths averted), per $100,000 spent (in 2011 US$), for each of nine interventions provided through universal public finance in Ethiopia. Source: adapted from [28]](https://figures.cochat.ai/paper-figures/67494259015c4f3688786f6899fff6c4/extended-cost-effectiveness-analysis-for-health-policy-assessment-a-tutorial-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The simulation modeling of behaviors and states builds upon the Extended Cost-Effectiveness Analysis (ECEA) model [32, 33], specifically the aggregated compartmental model used for studying the effect of cigarette price increases in middle-income countries [34].”
From Tobacco Taxes as the Unsung Hero: Impact of a Tax Increase on Advancing Sustainable Development in Colombia (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Awais, A. (2015) · Data Archiving and Networked Services (DANS) · doi:10.17632/zcvgc6m58h.1 · Cited by 6,707
Risk Aversion in the Small and in the Large
Pratt, J. W. (1964) · Econometrica · doi:10.2307/1913738 · Cited by 4,874
Risk Aversion in the Small and in the Large
Pratt, J. W. (1976) · Econometrica · doi:10.2307/1912743 · Cited by 4,654
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998 · cited 1×
“adherence to standard health economic methods and guidelines [2, 50] remains identical.”
BackgroundAspects of the Theory of Risk-Bearing.
Ozga, S. A., & Arrow, K. J. (1966) · Economica · doi:10.2307/2552628 · Cited by 1,888
Cost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552
Health systems financing and the path to universal coverage
Evans, D. B., & Etienne, C. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.10.078741 · Cited by 1,279
Rosenzweig, M. R., & Wolpin, K. I. (1993) · Journal of Political Economy · doi:10.1086/261874 · Cited by 1,179
Cited by
Knaul, F. M., Farmer, P. E., Krakauer, E. L., De Lima, L., Bhadelia, A., Jiang Kwete, X., Arreola-Ornelas, H., Gómez-Dantés, O., Rodriguez, N. M., Alleyne, G. A. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32513-8 · Cited by 1,456
Self-citationLakdawalla, D. N., Doshi, J. A., Garrison, L. P., Phelps, C. E., Basu, A., & Danzon, P. M. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.007 · Cited by 540
Using Cost-Effectiveness Analysis to Address Health Equity Concerns
Cookson, R., Mirelman, A. J., Griffin, S., Asaria, M., Dawkins, B., Norheim, O. F., Verguet, S., & J. Culyer, A. (2017) · Value in Health · doi:10.1016/j.jval.2016.11.027 · Cited by 327
Self-citationTurner, H. C., Archer, R. A., Downey, L. E., Isaranuwatchai, W., Chalkidou, K., Jit, M., & Teerawattananon, Y. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.722927 · Cited by 221
Kristensen, F. B., Husereau, D., Huić, M., Drummond, M., Berger, M. L., Bond, K., Augustovski, F., Booth, A., Bridges, J. F. P., Grimshaw, J., et al. (2018) · Value in Health · doi:10.1016/j.jval.2018.08.010 · Cited by 155
Metadata
- Authors
- Verguet, S., Kim, J. J., & Jamison, D. T.
- Affiliations
- Harvard University (US)
- University of California, San Francisco (US)
- Corresponding author
- Verguet, Stéphane
- Venue
- PharmacoEconomics
- Published
- 2016-07-04
- Volume
- 34
- Issue
- 9
- Pages
- 913-923
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- PMC
- PMC4980400
- OpenAlex
- W2470373670
- Cited by
- 251
- References
- 59
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 44 · 2023: 38 · 2022: 20 · 2021: 24 · 2020: 34 · 2019: 10 · 2018: 16 · 2017: 18 · 2016: 2
- FWCI
- 29.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- PharmacoEconomics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
- Keywords
- health policy evaluation, financial protection, health disparities, distributional effects, policy costs
- MeSH terms
- Cost-Benefit Analysis, Financing, Government, Health Policy, Humans, Insurance, Health, Public Health, Public Policy, Biomedical Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. https://app.cochat.ai/papers/10.1007/s40273-016-0414-z
- The paper
- Verguet, S., Kim, J. J., & Jamison, D. T. (2016). Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. https://doi.org/10.1007/s40273-016-0414-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.